Copernicus Therapeutics, Inc. to Further Development of Non-Viral Gene Therapy for Parkinson’s Disease
1/12/2009 8:43:20 AM
More...
|
Case Western Reserve University with Copernicus Therapeutics, Inc. and Polgenix Receive $3.9 Million from the Ohio Biomedical Research Commercialization Program (BRCP)
7/1/2008 1:17:31 PM
More...
|
Copernicus Therapeutics, Inc. Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics, Inc. to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis
12/11/2007 11:45:07 AM
More...
|
Copernicus Therapeutics, Inc.' Nanoparticle Technology Applied to siRNA
6/5/2007 12:33:16 PM
More...
|
Copernicus Therapeutics, Inc.: Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles
6/4/2007 12:15:32 PM
More...
|
Copernicus Therapeutics, Inc. To Receive Increased Support From Cystic Fibrosis Foundation Therapeutics, Inc. To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis
2/15/2007 11:47:54 AM
More...
|
Copernicus Therapeutics, Inc. Release: Manuscript Demonstrates Remarkable DNA Delivery And Expression In The Mouse Retina
1/9/2007 1:04:37 PM
More...
|
Copernicus Therapeutics, Inc. Demonstrates Ability Of Its Non-Viral Delivery System To Efficiently Transfer Large Sizes Of Nucleic Acid Into Lung Cells
7/7/2006 11:54:03 AM
More...
|
Copernicus Therapeutics, Inc. To Receive Continued Support From Cystic Fibrosis Foundation Therapeutics, Inc. To Further Develop Non-Viral Gene Therapy For Cystic Fibrosis
2/14/2006 12:51:40 PM
More...
|
Copernicus Therapeutics, Inc. Receives $1 Million From Cystic Fibrosis Foundation Therapeutics To Advance Development Of A Non-Viral Gene Therapy For Cystic Fibrosis
10/19/2005 5:12:27 PM
More...
|
|